Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. - Wikidata - wikimedia - TriplyDB

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.

http://www.wikidata.org/entity/Q42882546

about

Targeting folate receptor alpha for cancer treatment Profile of farletuzumab and its potential in the treatment of solid tumors A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Farletuzumab in lung cancer Antibody-based immunotherapy for ovarian cancer: where are we at?Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level The role of surgery in advanced epithelial ovarian cancer Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential Investigational agents in development for the treatment of ovarian cancer Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Antibody-based therapeutics to watch in 2011.Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.Immunity and immune suppression in human ovarian cancer.Immunotherapy for ovarian cancer.A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.Characterization of the human folate receptor alpha via novel antibody-based probes.Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.Folate, vitamin B(6) , vitamin B(12) , methionine and alcohol intake in relation to ovarian cancer risk.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia.Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha.Immunotherapy targets in pediatric cancer.Assessment of folate receptor-β expression in human neoplastic tissues.Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance.High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation Clinical utility of targeted treatments in the management of epithelial ovarian cancer.A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor Role of farletuzumab in epithelial ovarian carcinoma.Immunotherapy in ovarian cancer.Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease.

P2860

Q26744215-78A140CA-5D61-4B2D-9F4E-DE0670184D60 Q26750431-6D7408A1-2660-45E6-AD38-05034F38495C Q26781856-D66FDC67-5202-4E2D-9AE1-D7C423D6B762 Q26828581-87E17A14-D9F9-484E-BF34-FB236C4031AA Q26996829-F568A017-B0B0-4A1D-B3D1-F513CC206437 Q26997008-C73B5F0A-7342-4FB6-8606-D5DB09BD8E87 Q27000514-5ED463E6-B815-4F4D-B952-086DE3811A44 Q27300701-7B483DEF-72D3-44EA-9F09-0193D4BF2F24 Q28067698-E664A94C-AA89-45C4-8E5E-56EF1D3A0758 Q33618570-9CDFAC20-2A53-4173-AA7F-C46D6EBA1CCB Q33920800-0B657B1B-2B01-4F2B-8507-C5F267044C48 Q34016504-0A8DC9DD-82AF-4BDE-85F9-F56462C5CFC3 Q34033606-F14FDB3E-DFF7-444B-8265-F33A574242A5 Q34570079-09D6291D-ADEA-4738-80AF-59924D6B8ECF Q34687073-195BDF92-3ABD-43A0-987E-75A37217B07D Q34979610-5412394A-3CF1-4222-8B62-B2CD5B150CA9 Q35138135-FB9953F7-8B88-438E-B60D-B82625295042 Q35164189-266CE0B2-98EC-4136-957F-DD864999ECCE Q35288804-B779DF20-432E-42E9-8CAD-8A06D526E57A Q35764371-26EE289F-42B7-4AE8-A0C2-5749993C4A6B Q35766191-3CE49640-A59C-499A-B243-1E21BD3B02DC Q35780797-7E0A5AB3-4F16-4FB3-ADE9-0AC1CD108792 Q35784231-AC497AC0-563E-41C2-8741-3B11B1A7E172 Q35837949-190CB8FC-26A7-42F5-9A62-A186708FCBFA Q35854305-6AB3F31F-5363-42AF-BA89-B1C7DF5E3A10 Q35915267-14C47376-1127-4DD7-AAF5-20EF9F56EC98 Q35971029-243B7FCD-B6B6-4B47-96D0-3981DACB2DA9 Q35987448-1B93A9A4-70A7-4F45-B97C-AEAB550A1CE6 Q36050687-BD5D1D9A-8AFD-4DDF-B572-D3831229BAE8 Q36059727-6385E216-5771-4A00-BAB6-BEC104F263C8 Q36171268-3A6B7666-95AB-40A2-B33F-F222A451D38A Q36226627-3B9B57E3-8DE4-4FE9-AB89-E7FA39C61642 Q36361160-106981C5-8B9B-4447-96FF-DED58CED82B2 Q36470331-33C5CC46-ED12-4908-BDE2-669D87B740E0 Q36508941-DDE735BC-1A41-449D-B3E5-16C63BA245B2 Q36557169-D6199606-22F4-4588-B472-E9D9D0F40E50 Q36622914-D0647BD1-0D19-481F-9260-30D6BF1394F3 Q36631249-7001117B-1F73-45A2-8535-4DC85BB80225 Q36808757-A8C45218-6F27-498C-834B-2F2D90C70123 Q37052124-24A84124-B9F0-4448-BB30-138C7BB6F5CC

P2860

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.

http://www.wikidata.org/entity/Q42882546

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@en

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@nl

type

label

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@en

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@nl

prefLabel

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@en

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@nl

P1433

Q42882546-BECBF223-C693-4FED-92FB-55A51DF80D02

P1476

Q42882546-42BBA1BD-CC8B-4CEC-92A9-7791C0287245

P2093

Q42882546-1260F424-6F37-43AF-8666-78CCA2693D4D

Q42882546-154EA57E-0D57-4B4D-9BF2-AB94F97562C0

Q42882546-26873BC2-91A1-4A8C-B79B-A5E43BE47859

Q42882546-2D756D00-AC62-4300-B652-82818B36D832

Q42882546-64D0E3B7-D34E-48E7-A491-89379C72C62F

Q42882546-70B5A764-D2AB-4631-ADEE-BE7D40D85AAD

Q42882546-C505EAB7-A16A-4E07-8B76-3FE5DD7C53BE

Q42882546-D1683756-F68D-42D2-AAEE-6A627CB6F637

Q42882546-D2862BFA-4733-4F45-BD77-3C837D99542D

Q42882546-D2BEBB90-6D9B-4502-9081-B2225FF86CD9

P304

Q42882546-DC9FD681-6316-4282-B98F-1D8B9914361F

P31

Q42882546-4246EB08-6BC8-4887-BA8A-D1D291202F73

P356

Q42882546-83F07EA9-C9DF-4C37-A251-8CB7B432A7FB

P407

Q42882546-95FFB80F-9119-427A-BC7A-87586C5272EF

P433

Q42882546-486897B0-C5B0-450D-9FF6-C6957C89378E

P478

Q42882546-0DA9B7E1-4E39-449D-9AA2-5B3880043383

P50

Q42882546-B6AA313B-7110-48B6-872A-6D77B59BFD93

P577

Q42882546-DE7ED294-0ABE-45EB-B25D-4824FF4EC801

P698

Q42882546-33EBB38A-E5A2-44F0-9EC4-918BDF3CF09D

P921

Q42882546-16B9F717-06E9-4E0E-A55C-F906972FEB10

Q42882546-49265358-8AF9-482C-8002-92D8C586D583

P356

1078-0432.CCR-10-0700

P1433

Clinical Cancer Research

P1476

Farletuzumab, a humanized mono ...... arian cancer: a phase I study.

@en

P2093

Charles Schweizer

http://www.w3.org/2001/XMLSchema#string

Katherine M Bell-McGuinn

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Martee L Hensley

http://www.w3.org/2001/XMLSchema#string

Martin D Phillips

http://www.w3.org/2001/XMLSchema#string

Neeta Pandit-Taskar

http://www.w3.org/2001/XMLSchema#string

Nicholas Vander Els

http://www.w3.org/2001/XMLSchema#string

Paul Sabbatini

http://www.w3.org/2001/XMLSchema#string

Steven M Larson

http://www.w3.org/2001/XMLSchema#string

Susan C Weil

http://www.w3.org/2001/XMLSchema#string

P304

5288-5295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0700

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20855460

http://www.w3.org/2001/XMLSchema#string

P921